OBSERVATIONAL STUDY COMPARING TREATMENT PERSISTENCE IN BIOLOGIC NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR ETANERCEPT

被引：0
|
作者：
Clancy, Z. [1 ]
Tencer, T. [1 ]
Kaura, S. [1 ]
Li, S. [1 ]
机构：
[1] Celgene Corp, Summit, NJ USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS21
引用
收藏
页码：A159 / A159
页数：1
相关论文
共 50 条
  • [1] SWITCH PATTERNS AND TOTAL COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIASIS
    Wu, J.
    Pelletier, C.
    Ung, B.
    Tian, M.
    Ni, Q.
    Curtis, J. R.
    [J]. VALUE IN HEALTH, 2018, 21 : S426 - S426
  • [2] REAL WORLD COMPARISON OF PERSISTENCE AND ADHERENCE AMONG BIOLOGIC NAIVE PATIENTS INITIATING APREMILAST OR BIOLOGICS FOR THE TREATMENT OF PSORIASIS IN THE UNITED STATES
    Feldman, S. R.
    Bonafede, M. M.
    Pelletier, C.
    Mehta, R.
    Brouillette, M.
    Smith, D.
    Wilson, K. L.
    Ni, Q.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A566 - A566
  • [3] Persistence and Failure Rates of Monotherapy Etanercept in Biologic-Naive Psoriasis Patients: A Retrospective Study
    Reddy, Shivani P.
    Shah, Vidhi V.
    Lin, Elaine J.
    Egeberg, Alexander
    Wu, Jashin J.
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (08) : 1029 - 1030
  • [4] COMPARISON OF TREATMENT SWITCHING AMONG BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGIC TREATMENT: RESULTS FROM A US CLAIMS DATABASE
    Kaplan, D.
    Ung, B.
    Pelletier, C.
    Udeze, C.
    Tian, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S364 - S364
  • [5] TREATMENT PERSISTENCE IN PSORIASIS PATIENTS INITIATED ON APREMILAST, ORAL SYSTEMICS, OR BIOLOGIC THERAPIES
    Feldman, S. R.
    Kaura, S.
    Li, S.
    Tencer, T.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A805 - A805
  • [6] Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis
    Wu, Jashin J.
    Pelletier, Corey
    Ung, Brian
    Tian, Marc
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 365 - 371
  • [7] Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
    Feldman, Steven R.
    Pelletier, Corey L.
    Wilson, Kathleen L.
    Mehta, Rina K.
    Brouillette, Matthew A.
    Smith, David
    Bonafede, Machaon M.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (01) : 45 - 54
  • [8] Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics
    Wu, Jashin J.
    Pelletier, Corey
    Ung, Brian
    Tian, Marc
    Khilfeh, Ibrahim
    Curtis, Jeffrey R.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (11) : 767 - 779
  • [9] COMPARISON OF PERSISTENCE AND ADHERENCE IN BIOLOGIC NAIVE PATIENTS WITH PSORIATIC ARTHRITIS INITIATING APREMILAST OR BIOLOGICS IN A US ADMINISTRATIVE CLAIMS DATABASE
    Feldman, S. R.
    Bonafede, M. M.
    Pelletier, C.
    Mehta, R.
    Brouillette, M.
    Smith, D.
    Wilson, K. L.
    Ni, Q.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A541 - A541
  • [10] Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis
    Feldman, Steven R.
    Pelletier, Corey L.
    Wilson, Kathleen L.
    Mehta, Rina K.
    Brouillette, Matthew A.
    Smith, David
    Bonafede, Machaon M.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (09) : 699 - 708
12345